Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02194842 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase III Radium 223 mCRPC-PEACE III

Study acronym: PEACE III
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: 1 to 2
    • Secondary endpoints: 13 to 12
    v19
  2. Primary completion date changed from estimate of Mar 2024 to Feb 19, 2024
    • Study completion date: Dec 2025 to Dec 2028
    v18
  3. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 416 to confirmed 446
    • Study sites: 73 to 64
    • Primary completion date: Dec 2024 to Mar 2024
    v17
  4. Enrollment target: 560 to 416v16 Show 4 more changesShow less
    • Study sites: 54 to 73
    • Eligibility criteria expanded, about 836 words
    • Secondary endpoints: 12 to 13
    • Collaborators revised (6)
  5. Study sites: 47 to 54v15
Show 13 earlier versionsHide 13 earlier versions
  1. Primary completion date: Nov 2019 to Dec 2024
    • Study sites: 28 to 47
    • Study completion date: Apr 2021 to Dec 2025
    v14
  2. Study sites: 24 to 28v13
  3. Study sites: 20 to 24
    • Collaborators revised (6)
    v12
  4. Re-verified, no change to tracked fieldsv11
  5. Study sites: 17 to 20
    • Collaborators: 4 to 6
    v10
  6. Study sites: 15 to 17v9
  7. Study sites: 13 to 15v8
  8. Study sites: 11 to 13v7
  9. Study sites: 10 to 11v6
  10. Study sites: 6 to 10v5
  11. Study sites: 5 to 6v4
  12. Trial status: Not Yet Recruiting to Recruitingv3 Show 5 more changesShow less
    • Primary completion date: Oct 2018 to Nov 2019
    • Start date: Dec 2014 to Oct 2015
    • Study sites: 0 to 5
    • Study completion date: Mar 2020 to Apr 2021
    • Collaborators: 2 to 4
  13. Secondary endpoints: details revised at 11 of 12 entries
    • Collaborators expanded, about 5 words
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary objective of the trial is to assess if upfront combination of enzalutamide and Ra223 improves radiological progression-free survival (rPFS1) by investigator assessment compared to enzalutamide single agent in castration resistant prostate cancer (CRPC) patients metastatic to bone
Trial Details
NCT Number NCT02194842
Lead Sponsor European Organisation for Research and Treatment of Cancer - EORTC
Collaborators: Bayer, Astellas Pharma Europe Ltd., UNICANCER, Canadian Urologic Oncology Group, Latin American Cooperative Oncology Group, Cancer Trials Ireland
Conditions
(from sponsor)		 Prostate Cancer
Related terms Neoplasm Metastasis, Prostatic Neoplasms
Enrollment 446 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov